Operator
Thank you for standing by, and welcome to Kyntra Bio’s Fourth Quarter and Full Year 2025 Earnings Conference Call. [Operator Instructions].
I would now like to hand the call over to Gaia Shamis with LifeSci Advisors. Please go ahead.
Daia Vasiliver-Shamis
Kyntra Bio, Inc.
Thank you, operator. Good afternoon, everyone. Thank you for joining today to discuss Kyntra Bio’s Fourth Quarter and Full Year 2025 Financial and Business Results. I’m Gaia Shamis from LifeSci Advisors. Joining me on today’s call are Thane Wettig, Chief Executive Officer; David DeLucia, Chief Financial Officer; and Carol Gaddum, Vice President of Product Development. Following the prepared remarks, we will open the call to your questions.
I would like to remind you that remarks made on today’s call include forward-looking statements about Kyntra Bio. Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct and results of clinical trials, regulatory strategies and potential regulatory results, research and development activities, commercial results and results of operations, risks related to our business and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Kyntra Bio’s filings with the SEC, including our most recent Form 10-K and Form 10-Q.
Kyntra Bio does not
